Supplementary Figure 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

• Gut metabolite profiles were significantly associated with CAR-T therapy outcomes in multiple myeloma patients.
• Mean metabolite levels with standard deviation were presented for various metabolites observed before CAR-T infusion.
• The analysis was based on fecal samples collected from multiple myeloma patients prior to CAR-T treatment.
• Understanding microbiota roles may highlight new approaches for improving therapy responses in myeloma.